1. To understand the challenges in performing genome-wide studies to identify genetic markers associated with chemotherapeutic toxicities.
2. To understand both modifiable risk factors associated with cisplatin-induced ototoxicity and peripheral neuropathy.
3. To understand the lack of diversity in pharmacogenomic studies and its impact on health outcomes.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation